Highlands Oncology Group

Recent papers from Highlands Oncology Group

1. Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATEClinical Cancer Research · 2026
2. A first-in-human phase 1a study of LP-184, a tumor site–activated novel alkylating agent, in patients with advanced solid tumors.Journal of Clinical Oncology · 2026
3. National perspectives on artificial intelligence use in cancer care: Confidence, adoption, and barriers.Journal of Clinical Oncology · 2026
4. Phase 3 trial ResQ201A of nogapendekin alfa inbakicept (NAI) plus tislelizumab and docetaxel vs. docetaxel monotherapy for advanced or metastatic NSCLC resistant to ICI therapy.Journal of Clinical Oncology · 2026
5. Impact of remote therapeutic monitoring on time to discontinuation and acute care events among patients treated with immune checkpoint inhibitors.Journal of Clinical Oncology · 2026
6. Phase 1b study of a brain-penetrant MEK inhibitor, PF-07799544, plus next-generation BRAF dimer inhibitor, PF-07799933, in advanced BRAF -mutant melanoma.Journal of Clinical Oncology · 2026
7. Impact of remote therapeutic monitoring with patient-reported outcomes on hospitalization in real-world patients receiving therapy for metastatic solid tumors.Journal of Clinical Oncology · 2026
8. Abstract CT262: Elacestrant (Ela) in combination with everolimus (Eve) or abemaciclib (Abema) in patients with ER+/HER2- locally advanced or metastatic breast cancer mBC: phase 2 results from ELEVATE, an open-label, umbrella studyCancer Research · 2026
9. Remote Therapeutic Monitoring and Infection-Related Health Care Resource Utilization in Patients With Hematologic MalignanciesJCO Oncology Practice · 2026
10. Abstract PS3-08-06: Elegant: elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 studyClinical Cancer Research · 2026
11. Abstract PS5-03-12: Real-world BRCA and PD-L1 testing among first-line triple negative metastatic breast cancer patientsClinical Cancer Research · 2026
12. Abstract PS5-02-22: Impact of overall survival on the use of prophylactic granulocyte colony-stimulating factor with sacituzumab govitecan-hziy in the treatment of triple negative metastatic breast cancer patientsClinical Cancer Research · 2026
13. Abstract RF7-01: Elacestrant in combination with everolimus or abemaciclib in patients with ER+/HER2- locally advanced or metastatic breast cancer (mBC): phase 2 results from ELEVATE, an open-label, umbrella studyClinical Cancer Research · 2026
14. Abstract PS1-11-17: Real-world comparison of time to next treatment for patients with HR-positive, HER2-low metastatic breast cancer treated with either chemotherapy or trastuzumab deruxtecan in the second-lineClinical Cancer Research · 2026
15. Abstract PS5-01-12: Real-world time to next treatment in HER2+ breast cancer patients with brain metastases: trastuzumab deruxtecan vs tucatinib based therapy as second-line treatmentClinical Cancer Research · 2026
16. Abstract PS1-10-06: Impact of prior fulvestrant use and endocrine therapy duration on real-world outcomes of elacestrant treatment in ER+/HER2- metastatic breast cancerClinical Cancer Research · 2026
17. Abstract PS1-10-27: Progression-free survival (PFS) and overall survival (OS) results from the phase 3 MONALEESA-3 trial of postmenopausal patients with hormone receptor-positive (HR+)/HER2-negative (HER2−) advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL): A subgroup analysis of patients with invasive lobular carcinoma (ILC)Clinical Cancer Research · 2026
18. Abstract PS5-01-11: Impact of antiemetic strategy on overall survival in patients with metastatic HER2-positive breast cancer treated with trastuzumab deruxtecan: A real-world retrospective studyClinical Cancer Research · 2026
19. Abstract PS1-05-04: A multi-practice quality initiative evaluating antiemetic use in metastatic breast cancer patients treated with trastuzumab deruxtecan-nxki (T-DXd)Clinical Cancer Research · 2026
20. Abstract PS1-12-13: Real-world rate of switching and reasons for switching among CDK4/6i drugs among first-line metastatic HR+/HER2- breast cancer patientsClinical Cancer Research · 2026